Skylands Capital LLC Buys 45,650 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Skylands Capital LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 9.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 550,150 shares of the company's stock after purchasing an additional 45,650 shares during the period. Skylands Capital LLC owned 0.11% of Elanco Animal Health worth $5,777,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of ELAN. Kovack Advisors Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at about $170,000. Proficio Capital Partners LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter valued at about $405,000. QRG Capital Management Inc. bought a new position in shares of Elanco Animal Health in the 4th quarter valued at approximately $264,000. SRS Capital Advisors Inc. lifted its holdings in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its holdings in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Analysts Set New Price Targets

ELAN has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday. Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Finally, William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Elanco Animal Health currently has an average rating of "Moderate Buy" and an average price target of $15.33.

Elanco Animal Health Stock Performance

ELAN stock traded up $0.30 on Wednesday, reaching $14.73. 4,666,789 shares of the company were exchanged, compared to its average volume of 5,092,764. The firm has a market capitalization of $7.32 billion, a PE ratio of 19.91, a PEG ratio of 2.80 and a beta of 1.68. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $15.78. The stock's fifty day moving average price is $12.62 and its 200 day moving average price is $11.54. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm posted $0.34 EPS. The business's revenue was down 1.0% compared to the same quarter last year. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.